Edition:
United States

Chromadex Corp (CDXC.OQ)

CDXC.OQ on NASDAQ Stock Exchange Capital Market

6.54USD
3:59pm EST
Change (% chg)

$0.03 (+0.46%)
Prev Close
$6.51
Open
$6.48
Day's High
$6.60
Day's Low
$6.47
Volume
47,023
Avg. Vol
91,070
52-wk High
$7.24
52-wk Low
$2.26

Latest Key Developments (Source: Significant Developments)

ChromaDex Q3 loss per share $0.07 from continuing operations
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - ChromaDex Corp ::ChromaDex reports third quarter 2017 financial results.Q3 loss per share $0.07 from continuing operations.Q3 sales rose 55 percent to $6.1 million.  Full Article

Chromadex announces $23 mln private placement of common stock
Monday, 6 Nov 2017 06:30am EST 

Nov 6 (Reuters) - Chromadex Corp :Chromadex announces $23 million private placement of common stock.Chromadex Corp - in connection with investment, co agreed to sell 5.6 million shares of common stock at a per share price of $4.10​.Chromadex Corp - ‍net proceeds of investment expected to provide co added resources to accelerate plans related to nad+ in general, tru niagen in particular​.  Full Article

Chromadex Corp files for common stock‍​ offering by selling stockholders of up to $7.7 mln
Tuesday, 31 Oct 2017 04:59pm EDT 

Oct 31 (Reuters) - Chromadex Corp :Chromadex Corp files for common stock‍​ offering by selling stockholders of up to $7.7 million - SEC filing.  Full Article

Chromadex appoints Kevin Farr as new CFO
Monday, 9 Oct 2017 06:30am EDT 

Oct 9 (Reuters) - Chromadex Corp :Chromadex appoints Kevin Farr as new CFO.Chromadex Corp says ‍Chromadex expects that Thomas Varvaro will transition from Chromadex over coming months to pursue other opportunities​.  Full Article

Chromadex announces top-line results of its second human clinical trial
Tuesday, 26 Sep 2017 06:30am EDT 

Sept 26 (Reuters) - Chromadex Corp ::Chromadex announces top-line results of its second human clinical trial.Chromadex Corp - ‍results from trial demonstrated that NR produced statistically significant increases in blood NAD+ compared to placebo​.Chromadex Corp - ‍initial results of Niagen nicotinamide riboside chloride (NR) confirmed NR significantly raises co-enzyme NAD+ over 8-weeks.Chromadex Corp - ‍study establishes effective dose range and validates safety for Niagen nicotinamide riboside chloride in 140 humans over an 8-week period​.Chromadex Corp - ‍study confirms not only efficacy in raising NAD+, but also definitively documents safety of daily use of NR​.  Full Article

ChromaDex Partners with Watsons, for TRU NIAGEN retail launch
Thursday, 7 Sep 2017 06:30am EDT 

Sept 7 (Reuters) - Chromadex Corp :ChromaDex Corp - new partnership with Hong Kong based retailer, A.S. Watson, for launch of U.S. Made TRU NIAGEN) dietary supplement in Asia.  Full Article

Chromadex's units enter asset purchase agreement with Covance Laboratories Inc​
Wednesday, 23 Aug 2017 08:53am EDT 

Aug 23 (Reuters) - Chromadex Corp :Chromadex Corp - ‍on august 21, 2017, co's units entered into an asset purchase agreement with Covance Laboratories Inc​.Chromadex Corp - ‍pursuant to asset purchase agreement, co will sell operating assets its lab business to Covance.Chromadex Corp - ‍in consideration for lab business Covance will pay company an amount equal to $7.5 million​.  Full Article

Chromadex sells its analytical testing business to LabCorp
Wednesday, 23 Aug 2017 08:30am EDT 

Aug 23 (Reuters) - Chromadex Corp :Chromadex sells its analytical testing business to LabCorp, to accelerate the expansion of Nicotinamide Riboside and its other patented ingredient technologies.Chromadex Corp - ‍upon closing of transaction, analytical testing services will be offered through LabCorp's Covance Food Solutions business​.  Full Article

Chromadex announces closing of final tranche of $25 mln strategic investment and appoints two new board members
Monday, 21 Aug 2017 06:30am EDT 

Aug 21 (Reuters) - Chromadex Corp :Chromadex announces closing of third and final tranche of the $25 million strategic investment led by Mr. Li Ka-shing and appoints two additional board members.Chromadex - ‍In connection with strategic investment,champion river ventures nominated Tony Lau to board, Pioneer Step holdings nominated Wendy Yu to board.Chromadex Corp - ‍Board of directors subsequently appointed Lau and Yu as directors on August 18, 2017​.  Full Article

ChromaDex Q2 loss per share $0.07
Thursday, 10 Aug 2017 04:05pm EDT 

Aug 10 (Reuters) - Chromadex Corp :ChromaDex reports second quarter 2017 financial results.Q2 sales $5.3 million versus $8.8 million.Q2 loss per share $0.07.  Full Article

BRIEF-ChromaDex Corp qtrly ‍reported net sales of $6.1 million from continuing operations

* Chromadex Corp - qtrly ‍reported net sales of $6.1 million from continuing operations compared to $3.9 million for Q3 of 2016​ Source text: (http://bit.ly/2zpFLpg) Further company coverage: